In the RESPONSE study, among 104 JAK2-positive PV patients treated with RUX, a gradual response was seen in the mean JAK2 VAF, and after 208 weeks the mean reduction was 40% (relative) (15). Here, JAK2 is linked to acquired polycythemia vera.